Aurobindo Pharma Ltd has received USFDA approval to market potassium chloride tablets of 600 mg and 750 mg in the US market. The tablet, a generic version of Upsher-Smith’s Klor-Con extended release tablets is likely to be launched next month. The drug – potassium chloride tablets are used for treating hypokalemia, a condition wherein there is a drop in the potassium-level in the blood.
According to market estimates, the drug has an estimated market size of USD 60 million for 12 months ending October 2018.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply